Posted by Michael Wonder on 27 Mar 2024
Takeda announces approval of Adzynma intravenous injection 1500 (apadamtase alfa/cinaxadamtase alfa) in Japan for patients with congenital thrombotic thrombocytopenic purpura
26 March 2024 - Adzynma (apadamtase alfa/cinaxadamtase alfa) is the first and only recombinant ADAMTS13 enzyme replacement therapy for people with congenital thrombotic thrombocytopenic purpura.
Takeda today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Adzynma (apadamtase alfa/cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura for individuals 12 years of age and older.
